keyword
MENU ▼
Read by QxMD icon Read
search

Breast cancer immunotherapy

keyword
https://www.readbyqxmd.com/read/29928442/a-novel-potential-effective-strategy-for-enhancing-the-antitumor-immune-response-in-breast-cancer-patients-using-a-viable-cancer-cell-dendritic-cell-based-vaccine
#1
Mona S Abdellateif, Sabry M Shaarawy, Eman Z Kandeel, Ahmed H El-Habashy, Mohamed L Salem, Motawa E El-Houseini
Dendritic cells (DCs) have been used in a number of clinical trials for cancer immunotherapy; however, they have achieved limited success in solid tumors. Consequently the aim of the present study was to identify a novel potential immunotherapeutic target for breast cancer patients through in vitro optimization of a viable DC-based vaccine. Immature DCs were primed by viable MCF-7 breast cancer cells and the activity and maturation of DCs were assessed through measuring CD83, CD86 and major histocompatibility complex (MHC)-II expression, in addition to different T cell subpopulations, namely CD4+ T cells, CD8+ T cells, and CD4+ CD25+ forkhead box protein 3 (Foxp3)+ regulatory T cells (Tregs), by flow cytometric analysis...
July 2018: Oncology Letters
https://www.readbyqxmd.com/read/29928319/canine-mammary-tumors-as-a-model-for-human-disease
#2
REVIEW
Somaia M Abdelmegeed, Sulma Mohammed
Animal models for examining human breast cancer (HBC) carcinogenesis have been extensively studied and proposed. With the recent advent of immunotherapy, significant attention has been focused on the dog as a model for human cancer. Dogs develop mammary tumors and other cancer types spontaneously with an intact immune system, which exhibit a number of clinical and molecular similarities to HBC. In addition to the spontaneous tumor presentation, the clinical similarities between human and canine mammary tumors (CMT) include the age at onset, hormonal etiology and course of the diseases...
June 2018: Oncology Letters
https://www.readbyqxmd.com/read/29926750/cancer-testis-antigens-as-immunogenic-and-oncogenic-targets-in-breast-cancer
#3
Abeer M Mahmoud
Breast cancer cells frequently express tumor-associated antigens that can elicit immune responses to eradicate cancer. Cancer-testis antigens (CTAs) are a group of tumor-associated antigens that might serve as ideal targets for cancer immunotherapy because of their cancer-restricted expression and robust immunogenicity. Previous clinical studies reported that CTAs are associated with negative hormonal status, aggressive tumor behavior and poor survival. Furthermore, experimental studies have shown the ability of CTAs to induce both cellular and humoral immune responses...
June 21, 2018: Immunotherapy
https://www.readbyqxmd.com/read/29923634/radioimmunoimaging-and-targeting-treatment-in-an-immunocompetent-murine-model-of-triple-negative-breast-cancer-using-radiolabeled-anti-pd-l1-monoclonal-antibody
#4
Xiaoxi Pang, Meng Liu, Rongfu Wang, Xuhe Liao, Ping Yan, Chunli Zhang
The overall aim of this study was to evaluate whether iodine-131 radiolabeled monoclonal antibody (mAb) targeting PD-L1 can be used for imaging of PD-L1 expression noninvasively in vivo, and playing synergistic effect combined with immunotherapy. Anti-PD-L1 mAb was radiolabeled with iodine-131 (131 I-PD-L1 mAb), and was characterized in vitro. Biodistribution and imaging in vivo were performed periodically. Therapy study was conducted in triple-negative breast cancer bearing BALB/c mice. As results, the labeling efficiencies of 131 I-PD-L1 mAb reached 80 % ± 3 %, with radiochemical purity was 97 % ± 1 %...
June 20, 2018: Journal of Labelled Compounds & Radiopharmaceuticals
https://www.readbyqxmd.com/read/29917141/tumor-cdkn2a-associated-jak2-loss-and-susceptibility-to-immunotherapy-resistance
#5
Susanne Horn, Sonia Leonardelli, Antje Sucker, Dirk Schadendorf, Klaus G Griewank, Annette Paschen
Poor clinical responses to checkpoint blockade with anti-CTLA-4 and anti-PD-1 antibodies in melanoma have recently been associated with acquired IFNγ resistance that protects tumor cells from the antiproliferative and pro-apoptotic cytokine activity. IFNγ-resistant melanoma cells very often lack functional expression of the IFNγ signaling pathway gene JAK2 due to gene deletions or inactivating gene mutations. Analyzing melanoma cell lines (n = 46, applying next-generation targeted sequencing and single nucleotide polymorphism arrays) as well as available genomic data sets from The Cancer Genome Atlas (TCGA) tumor tissue samples (cutaneous melanoma n = 367, lung squamous cell carcinoma n = 501, bladder urothelial carcinoma n = 408, breast invasive carcinoma n = 768, colorectal adenocarcinoma n = 257), we demonstrate that the frequent chromosomal losses of the tumor suppressor CDKN2A in melanoma and other tumor entities enhance the susceptibility to IFNγ resistance by concomitant deletion of the JAK2 gene (odds ratio = 223...
June 1, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29916188/new-horizons-in-breast-cancer-the-promise-of-immunotherapy
#6
REVIEW
L de la Cruz-Merino, N Palazón-Carrión, F Henao-Carrasco, E Nogales-Fernández, M Álamo-de la Gala, A Vallejo-Benítez, M Chiesa, V Sánchez-Margalet
Immunology and immunotherapy of cancer is an expanding field in oncology, with recent great achievements obtained through the new successful approaches implemented to circumvent immune evasion, which is undoubtedly considered a novel hallmark of cancer. Translational research in this topic has revealed targets that can be modulated in the clinical setting with new compounds and strategies. Like most of the tumors, breast cancer is considered a complex and heterogeneous disease in which host immune responses have been also recently demonstrated of critical relevance...
June 18, 2018: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29911111/understanding-patterns-of-brain-metastasis-in-breast-cancer-and-designing-rational-therapeutic-strategies
#7
REVIEW
Evelyn M Brosnan, Carey K Anders
One of the most feared sequelae after a diagnosis of advanced breast cancer is development of metastases to the brain as this diagnosis can affect physical function, independence, relationships, quality of life, personality, and ultimately one's sense of self. The propensity to develop breast cancer brain metastases (BCBMs) varies by subtype, occurring in up to one half of those with triple negative breast cancer (TNBC), approximately a third of HER+ breast cancers and 14% in hormone positive disease. Median survival after BCBM diagnosis can be as short as 5 months in TNBC and 10-18 months in the other subtypes...
May 2018: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29910657/advances-in-the-systemic-treatment-of-triple-negative-breast-cancer
#8
REVIEW
J M Lebert, R Lester, E Powell, M Seal, J McCarthy
Triple-negative breast cancer constitutes a heterogeneous group of malignancies that are often aggressive and associated with a poor prognosis. Molecular characterization, while not a standard of care, can further subtype triple-negative breast cancer and provide insight into prognostication and behaviour. Optimal chemotherapy regimens have yet to be established; however, there have been advances in the systemic treatment of triple-negative breast cancer in the neoadjuvant, adjuvant, and metastatic settings...
June 2018: Current Oncology
https://www.readbyqxmd.com/read/29907693/exosomes-shuttle-trex1-sensitive-ifn-stimulatory-dsdna-from-irradiated-cancer-cells-to-dendritic-cells
#9
Julie M Diamond, Claire Vanpouille-Box, Sheila Spada, Nils-Petter Rudqvist, Jessica Chapman, Beatrix Ueberheide, Karsten A Pilones, Yasmeen Sarfraz, Silvia C Formenti, Sandra Demaria
Radiotherapy (RT) used at immunogenic doses leads to accumulation of cytosolic double-stranded DNA (dsDNA) in cancer cells, which activates type I IFN (IFN-I) via the cGAS/STING pathway. Cancer cell-derived IFN-I is required to recruit BATF3-dependent dendritic cells (DCs) to poorly immunogenic tumors and trigger antitumor T-cell responses in combination with immune checkpoint blockade. We have previously demonstrated that the exonuclease TREX1 regulates radiation immunogenicity by degrading cytosolic dsDNA...
June 15, 2018: Cancer Immunology Research
https://www.readbyqxmd.com/read/29899661/breast-cancer-immunotherapy-an-update
#10
REVIEW
Issam Makhoul, Mohammad Atiq, Ahmed Alwbari, Thomas Kieber-Emmons
The immune system plays a major role in cancer surveillance. Harnessing its power to treat many cancers is now a reality that has led to cures in hopeless situations where no other solutions were available from traditional anticancer drugs. These spectacular achievements rekindled the oncology community's interest in extending the benefits to all cancers including breast cancer. The first section of this article reviews the biological foundations of the immune response to different subtypes of breast cancer and the ways cancer may overcome the immune attack leading to cancer disease...
2018: Breast Cancer: Basic and Clinical Research
https://www.readbyqxmd.com/read/29896282/aerosol-immunotherapy-with-or-without-cisplatin-for-metastatic-lung-cancer-non-small-cell-lung-cancer-disease-in-vivo-study-a-more-efficient-combination
#11
Konstantinos Sapalidis, Paul Zarogoulidis, Efstathios Pavlidis, Stella Laskou, Athanasios Katsaounis, Charilaos Koulouris, Dimitrios Giannakidis, Stylianos Mantalovas, Haidong Huang, Chong Bai, Yuting Wen, Li Wang, Chrysanthi Sardeli, Aikaterini Amaniti, Ilias Karapantzos, Chrysanthi Karapantzou, Wolfgang Hohenforst-Schmidt, Fotis Konstantinou, Isaak Kesisoglou, Naim Benhanseen
Lung cancer is the leading cause of cancer death after prostate cancer for males and breast cancer for females. There are novel therapies in the past five years such as; tyrosine kinase inhibitors and most recently in the last two years immunotherapy. Immunotherapy is currently being investigated if it can be administered alone or in combination. Previously we have investigated whether immunotherapy compounds can be produced as aerosols, and in the current study we investigated the safety and efficiency independently of the programmed death-ligand 1...
2018: Journal of Cancer
https://www.readbyqxmd.com/read/29881518/immunotherapy-in-breast-cancer-the-new-frontier
#12
REVIEW
Zishuo I Hu, Heather L McArthur
Purpose of review: This review summarizes current immunotherapies in breast cancer, with an emphasis on immune checkpoint inhibitors and vaccines. Recent findings: Combination immunotherapy with checkpoint inhibitors and cytotoxic therapies have shown promising results. Active clinical trials are ongoing in both early stage and metastatic settings for triple negative, HER2+, and hormone-positive breast cancer patients. Summary: Ongoing challenges remain in defining biomarkers that predict response to immunotherapy, determining the optimal combination immunotherapies, and enhancing the immunogenicity of breast cancer subtypes...
2018: Current Breast Cancer Reports
https://www.readbyqxmd.com/read/29878901/dz-2384-has-a-superior-preclinical-profile-to-taxanes-for-the-treatment-of-triple-negative-breast-cancer-and-is-synergistic-with-anti-ctla-4-immunotherapy
#13
Cynthia Bernier, Ahmed Soliman, Michel Gravel, Matthew Dankner, Paul Savage, Kevin Petrecca, Morag Park, Peter M Siegel, Gordon C Shore, Anne Roulston
Triple-negative breast cancer (TNBC) is typically aggressive, difficult to treat, and commonly metastasizes to the visceral organs and soft tissues, including the lungs and the brain. Taxanes represent the most effective and widely used therapeutic class in metastatic TNBC but possess limiting adverse effects that often result in a delay, reduction, or cessation of their use. DZ-2384 is a candidate microtubule-targeting agent with a distinct mechanism of action and strong activity in several preclinical cancer models, with reduced toxicities...
June 6, 2018: Anti-cancer Drugs
https://www.readbyqxmd.com/read/29878757/photothermal-activatable-fe-3-o-4-superparticle-nanodrug-carriers-with-pd-l1-immune-checkpoint-blockade-for-anti-metastatic-cancer-immunotherapy
#14
Rui Ge, Cangwei Liu, Xue Zhang, Wenjing Wang, Binxi Li, Jie Liu, Yi Liu, Hongchen Sun, Daqi Zhang, Yuchuan Hou, Hao Zhang, Bai Yang
Checkpoint blockade immunotherapy has shown great potential in clinical cancer therapy, but the body's systemic immune must be fully activated and generates a positive tumor-specific immune cell response. In this work, we demonstrate the design of the immune-adjuvant nanodrug carriers on the basis of poly(ethylene glycol)- block-poly(lactic- co-glycolic acid) copolymer-encapsulated Fe3 O4 superparticles (SPs), in which imiquimod (R837), a kind of Toll-like receptor 7 agonist, is loaded. The nanodrug carriers are defined as Fe3 O4 -R837 SPs...
June 7, 2018: ACS Applied Materials & Interfaces
https://www.readbyqxmd.com/read/29874101/her2-based-immunotherapy-for-breast-cancer
#15
Naipeng Cui, Jianhong Shi, Chuanwei Yang
Resistance to therapies and disease recurrences after surgery or treatment are common challenges in breast cancer management in clinic. Active immunotherapy using human epidermal growth factor receptor 2 (HER2)-targeted vaccines represents an attractive option in combating breast cancer. Different HER2-derived vaccines have been developed over the years. Many clinical trials have been carried out in evaluating HER2-based vaccines. The authors reviewed current literature on HER2-based vaccines in clinical trials...
June 6, 2018: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/29870916/emerging-therapeutic-modalities-of-parp-inhibitors-in-breast-cancer
#16
REVIEW
Xin Wang, Yaqin Shi, Doudou Huang, Xiaoxiang Guan
Inhibition of Poly (ADP-ribose) polymerase (PARP) has shown marked benefit for breast cancer with homologous recombination deficiency, whether driven by defects in BRCA1, BRCA2, or other pathway components. Since the initial approval of olaparib, a mostly investigated PARP inhibitor (PARPi), the clinical development of PARPi in breast cancer treatment has been a major emphasis. Researches in investigating platinum-PARPi combination use compared with platinum monotherapy demonstrated promising benefit in metastatic BRCA mutated breast cancer or TNBC, while no such superiority was observed in the neoadjuvant setting of TNBC...
May 31, 2018: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29867922/sv-br-1-gm-a-clinically-effective-gm-csf-secreting-breast-cancer-cell-line-expresses-an-immune-signature-and-directly-activates-cd4-t-lymphocytes
#17
Markus D Lacher, Gerhard Bauer, Brian Fury, Sanne Graeve, Emily L Fledderman, Tye D Petrie, Dane P Coleal-Bergum, Tia Hackett, Nicholas H Perotti, Ying Y Kong, William W Kwok, Joseph P Wagner, Charles L Wiseman, William V Williams
Targeted cancer immunotherapy with irradiated, granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting, allogeneic cancer cell lines has been an effective approach to reduce tumor burden in several patients. It is generally assumed that to be effective, these cell lines need to express immunogenic antigens coexpressed in patient tumor cells, and antigen-presenting cells need to take up such antigens then present them to patient T cells. We have previously reported that, in a phase I pilot study (ClinicalTrials...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29867227/immune-recognition-of-somatic-mutations-leading-to-complete-durable-regression-in-metastatic-breast-cancer
#18
Nikolaos Zacharakis, Harshini Chinnasamy, Mary Black, Hui Xu, Yong-Chen Lu, Zhili Zheng, Anna Pasetto, Michelle Langhan, Thomas Shelton, Todd Prickett, Jared Gartner, Li Jia, Katarzyna Trebska-McGowan, Robert P Somerville, Paul F Robbins, Steven A Rosenberg, Stephanie L Goff, Steven A Feldman
Immunotherapy using either checkpoint blockade or the adoptive transfer of antitumor lymphocytes has shown effectiveness in treating cancers with high levels of somatic mutations-such as melanoma, smoking-induced lung cancers and bladder cancer-with little effect in other common epithelial cancers that have lower mutation rates, such as those arising in the gastrointestinal tract, breast and ovary1-7 . Adoptive transfer of autologous lymphocytes that specifically target proteins encoded by somatically mutated genes has mediated substantial objective clinical regressions in patients with metastatic bile duct, colon and cervical cancers8-11 ...
June 2018: Nature Medicine
https://www.readbyqxmd.com/read/29862083/the-evolution-of-radiation-therapy-in-metastatic-breast-cancer-from-local-therapy-to-systemic-agent
#19
REVIEW
Jessica M S Jutzy, Jeffrey M Lemons, Jason J Luke, Steven J Chmura
Radiation therapy is a mainstay of treatment in early and locally advanced breast cancer but is typically reserved for palliation of symptomatic lesions in patients with metastatic breast cancer. With new advances in the field of tumor biology and immunology, the role of radiation in the metastatic setting is evolving to harness its immune-enhancing properties. Through the release of tumor antigens, tumor DNA, and cytokines into the tumor microenvironment, radiation augments the antitumoral immune response to affect both the targeted lesion and distant sites of metastatic disease...
2018: International Journal of Breast Cancer
https://www.readbyqxmd.com/read/29860986/immunotherapy-and-prevention-of-pancreatic-cancer
#20
REVIEW
Alexander H Morrison, Katelyn T Byrne, Robert H Vonderheide
Pancreatic cancer is the third-leading cause of cancer mortality in the USA, recently surpassing breast cancer. A key component of pancreatic cancer's lethality is its acquired immune privilege, which is driven by an immunosuppressive microenvironment, poor T cell infiltration, and a low mutational burden. Although immunotherapies such as checkpoint blockade or engineered T cells have yet to demonstrate efficacy, a growing body of evidence suggests that orthogonal combinations of these and other strategies could unlock immunotherapy in pancreatic cancer...
June 2018: Trends in Cancer
keyword
keyword
25007
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"